| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/06/2013 | US8501908 Immunogenic peptides |
| 08/06/2013 | US8501707 Mucin antigen vaccine |
| 08/06/2013 | US8501702 Alone or in combination with a Wnt signaling antagonist; multiple myeloma, osteoporosis, post-menopausal osteoporosis, fractures, metastatic breast cancer or metastatic prostate cancer |
| 08/06/2013 | US8501427 Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration |
| 08/06/2013 | US8501423 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
| 08/06/2013 | US8501417 Immunological compositions as cancer biomarkers and/or therapeutics |
| 08/06/2013 | US8501240 Compositions comprising an active agent |
| 08/06/2013 | US8501221 Methods for preparing and delivering adjuvant compositions |
| 08/06/2013 | US8501220 Stabilized liquid egg material for extended shelf life |
| 08/06/2013 | US8501198 Tissue targeted antigenic activation of the immune response to treat cancers |
| 08/06/2013 | US8501197 Compositions and methods for stimulating immune response against Moraxella catarrhalis |
| 08/06/2013 | US8501196 Pharmaceutical compositions containing botulinum neurotoxin |
| 08/06/2013 | US8501195 Injection paradigm for administration of botulinum toxins |
| 08/06/2013 | US8501194 Vaccine for viruses that cause persistent or latent infections |
| 08/06/2013 | US8501193 Stabilized Tat antigen and the use thereof for anti-HIV vaccination |
| 08/06/2013 | US8501192 Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis |
| 08/06/2013 | US8501191 FGFR2-IIIb fusion proteins and methods of making them |
| 08/06/2013 | US8501190 Vaccine against Clostridium perfringens |
| 08/06/2013 | US8501189 Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases |
| 08/06/2013 | US8501188 Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
| 08/06/2013 | US8501187 Stabilized biodegradable neurotoxin implants |
| 08/06/2013 | US8501186 Adjuvant composition for vaccine |
| 08/06/2013 | US8501185 Dimeric molecular complexes |
| 08/06/2013 | US8501184 High affinity human antibodies to PCSK9 |
| 08/06/2013 | US8501183 Immunogenic compositions and diagnostic and therapeutic uses thereof |
| 08/06/2013 | US8501182 Monoclonal antibodies that react with the capsule of Bacillus anthracis |
| 08/06/2013 | US8501181 Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins |
| 08/06/2013 | US8501180 Anti system ASC amino acid transporter 2 (ASCT2) antibody |
| 08/06/2013 | US8501179 Antibody against PcrV |
| 08/06/2013 | US8501178 Use of DR6 and p75 antagonists to promote survival of cells of the nervous system |
| 08/06/2013 | US8501177 Treatment of ectodermal dysplasia with EDA1 fusion proteins |
| 08/06/2013 | US8501176 Methods of reducing eosinophil levels |
| 08/06/2013 | US8501174 Prevention and treatment of ocular side effects with a cyclosporin |
| 08/06/2013 | US8501173 Antibodies to high mobility group-1(HMGB1) B-box polypeptides |
| 08/06/2013 | US8501172 pH-induced silk gels and uses thereof |
| 08/06/2013 | US8501171 Use of ADCC-optimized antibodies for treating weak patients |
| 08/06/2013 | US8501168 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods |
| 08/06/2013 | US8501167 Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| 08/06/2013 | US8501157 Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies |
| 08/06/2013 | CA2844264A1 Optimized antigens of pneumocystis and use thereof |
| 08/06/2013 | CA2689696C Microemulsions with adsorbed macromolecules and microparticles |
| 08/06/2013 | CA2598684C Porcine helicobacter infection |
| 08/06/2013 | CA2526509C Connective tissue growth factor antibodies |
| 08/06/2013 | CA2522580C A medicament for the two-step perioperative therapy of solid tumours |
| 08/06/2013 | CA2521826C Recombinant il-9 antibodies and uses thereof |
| 08/06/2013 | CA2489214C Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers |
| 08/06/2013 | CA2388807C Viruses for the treatment of cellular proliferative disorders |
| 08/06/2013 | CA2358385C Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 08/06/2013 | CA2326685C Enhancing immune responses to genetic immunization by using a chemokine |
| 08/01/2013 | WO2013113008A1 Growth differentiation factor 15 (gdf-15) polypeptides |
| 08/01/2013 | WO2013112995A1 Influenza c virus and vaccine |
| 08/01/2013 | WO2013112948A1 Benchmarks for normal cell identification |
| 08/01/2013 | WO2013112945A1 Humanized antibodies that recognize alpha-synuclein |
| 08/01/2013 | WO2013112922A1 Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| 08/01/2013 | WO2013112916A1 Composite antigenic sequences and vaccines |
| 08/01/2013 | WO2013112856A2 Multifunctional nanomaterials for the treatment of cancer |
| 08/01/2013 | WO2013112801A1 Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities |
| 08/01/2013 | WO2013112720A1 Parainfluenza virus 5 based vaccines |
| 08/01/2013 | WO2013112690A1 Piv5 as oncolytic agent |
| 08/01/2013 | WO2013112549A1 Polynucleotides for treating oncogenic viral polypeptide positive tumors |
| 08/01/2013 | WO2013112438A1 Stabilized formulations containing anti-ang2 antibodies |
| 08/01/2013 | WO2013111770A1 Novel anti-malignant tumor agent |
| 08/01/2013 | WO2013111714A1 Prophylactic or therapeutic agent for bronchial asthma and method for screening same |
| 08/01/2013 | WO2013111084A1 Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria |
| 08/01/2013 | WO2013111014A2 Methods and compositions for treating neuron loss in inflammatory bowel disease |
| 08/01/2013 | WO2013110946A1 Combined therapeutic use of antibodies and endoglycosidases |
| 08/01/2013 | WO2013110824A1 Multi-component chimera for use as a vaccine against infection by leishmania spp. in mammals |
| 08/01/2013 | WO2013110790A1 Vaccine compositions for hiv prevention and treatment |
| 08/01/2013 | WO2013110163A1 Compositions and methods of modulating an immune response |
| 08/01/2013 | WO2013055058A3 Antibody-binding peptide-ferritin fusion protein and uses thereof |
| 08/01/2013 | WO2013054199A3 Cmv antigens and uses thereof |
| 08/01/2013 | WO2012085668A3 Compounds |
| 08/01/2013 | WO2012064733A3 Antibody scaffold for homogenous conjugation |
| 08/01/2013 | WO2008028501A8 Methods for blocking the interaction between nkp80 and its ligand aicl |
| 08/01/2013 | US20130198876 Induced malignant stem cells or pre-induction cancer stem cells capable of selfreplication outside of an organism, production method for same, and practical application for same |
| 08/01/2013 | US20130196427 Cancer antigen peptides derived from wt1 |
| 08/01/2013 | US20130195984 Combinations and modes of administration of therapeutic agents and combination therapy |
| 08/01/2013 | US20130195969 Small liposomes for delivery of immunogen encoding rna |
| 08/01/2013 | US20130195963 Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
| 08/01/2013 | US20130195961 Novel mucosal vaccination approach for herpes simplex virus type-2 |
| 08/01/2013 | US20130195930 Inulin and Inulin Acetate Formulations |
| 08/01/2013 | US20130195923 Microemulsions with adsorbed macromolecules and microparticles |
| 08/01/2013 | US20130195917 Immunoadjuvant |
| 08/01/2013 | US20130195915 Influenza C Virus and Vaccine |
| 08/01/2013 | US20130195914 Expression Of Positive Sense Single Stranded RNA Virus And Uses Thereof |
| 08/01/2013 | US20130195913 Live attenuated parvovirus |
| 08/01/2013 | US20130195910 Vaccine delivery method |
| 08/01/2013 | US20130195907 Omv vaccines |
| 08/01/2013 | US20130195906 H3 equine influenza a virus |
| 08/01/2013 | US20130195904 Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications |
| 08/01/2013 | US20130195903 Compositions for use in the treatment of chronic obstructive pulmonary diseases and asthma |
| 08/01/2013 | US20130195902 Recombinant allergen |
| 08/01/2013 | US20130195898 Microemulsions with adsorbed macromolecules and microparticles |
| 08/01/2013 | US20130195897 Removal of serine proteases by treatment with finely divided silicon dioxide |
| 08/01/2013 | US20130195896 Compositions and methods for the treatment of a neoplasia |
| 08/01/2013 | US20130195895 Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| 08/01/2013 | US20130195894 Detection and treatment of autoimmune disorders |
| 08/01/2013 | US20130195893 Use of a pneumococcal p4 peptide for enhancing opsonophagocytosis in response to a pathogen |
| 08/01/2013 | US20130195892 Bvdv vaccine |
| 08/01/2013 | US20130195891 Micro-RNA family that Modulates Fibrosis and Uses Thereof |